Abivax Demonstrates Anti-Fibrotic Potential of Obefazimod at ECCO 2026
Abivax presented evidence that obefazimod shows anti-fibrotic potential in IBD treatment with good safety profile. Phase 3 results expected mid-2026.
ABVXPhase 3 clinical trialsbiomarkers